Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Lung Neoplasms × capmatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 1 Lung Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Adenocarcinoma of Lung 1

Interventions

selpercatinib 2 tremelimumab 1 repotrectinib 1 pralsetinib 1 encorafenib 1 durvalumab 1 ceritinib 1 capmatinib 1 brigatinib 1 binimetinib 1 Pemetrexed 1 Crizotinib 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02414139 2024-03-20

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Novartis

Phase 2 Completed

373 enrolled 34 charts 3 FDA

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡